黑料网

Abstract

Mild dementia or mild cognitive impairment (MCI) causes slight but measurable cognitive changes like decline in memory and thinking skills which can easily be noticed by the individuals experiencing them or to other people. There is no certainty that MCI get worse or patient may feel eventually better. It is classified on the basis of thinking skills affected like amnestic MCI (memory affected) and non-amnestic MCI (thinking skills affected along with memory). High blood pressure, high cholesterol, type 1 diabetes and smoking are the factors which promotes the risk of dementia. Management of these factors may reduce its risk. A number of medications have been shown to be effective in treating mild, moderate and severe dementia. Donepezil, memantine hydrochloride, antipsychotics and acetylcholine-esterase inhibitors (such as galantamine and rivastigmine) are used to treat dementia. Furthermore, numerous new strategies are emerging for the management of dementia like nanotechnology i.e., development of nano-particles. Nano-particles are formulations of synthetic, chemical components that self-assemble on mixing into particles of less than 100 nm. Nanostructure mediated drug delivery enhances drug bioavailability, improves the timed release of drug molecules, and enables precision drug targeting. The nano-particle components that will be designed and synthesized will comprise novel peptides and lipids with smart properties, such as receptor targeting, stealth coatings, bio-responsive linkers for disassembly, and biocompatibility. A plethora of research findings are available for the treatment of dementia. This new nanotechnologies could transform the management of patients with dementias with enormous potential benefits to the world and the economy.

Biography

Email: unagaich@amity.edu  upendra_nagaich@hotmail.com